These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 1505197)

  • 1. A comparison of intraocular pressure elevating activity of loteprednol etabonate and dexamethasone in rabbits.
    Bodor N; Bodor N; Wu WM
    Curr Eye Res; 1992 Jun; 11(6):525-30. PubMed ID: 1505197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of loteprednol/tobramycin versus dexamethasone/tobramycin on intraocular pressure in healthy volunteers.
    Holland EJ; Bartlett JD; Paterno MR; Usner DW; Comstock TL
    Cornea; 2008 Jan; 27(1):50-5. PubMed ID: 18245967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loteprednol etabonate: comparison with other steroids in two models of intraocular inflammation.
    Howes JF; Baru H; Vered M; Neumann R
    J Ocul Pharmacol; 1994; 10(1):289-93. PubMed ID: 8207332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraocular pressure elevations with loteprednol etabonate: a retrospective chart review.
    Rajpal RK; Digby D; D'Aversa G; Mah F; Hollander DA; Conway T
    J Ocul Pharmacol Ther; 2011 Jun; 27(3):305-8. PubMed ID: 21574815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The conjunctival provocation test model of ocular allergy: utility for assessment of an ocular corticosteroid, loteprednol etabonate.
    Abelson M; Howes J; George M
    J Ocul Pharmacol Ther; 1998 Dec; 14(6):533-42. PubMed ID: 9867336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loteprednol etabonate ophthalmic suspension 0.5 %: efficacy and safety for postoperative anti-inflammatory use.
    Amon M; Busin M
    Int Ophthalmol; 2012 Oct; 32(5):507-17. PubMed ID: 22707339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular Pressure.
    Sheppard JD; Comstock TL; Cavet ME
    Adv Ther; 2016 Apr; 33(4):532-52. PubMed ID: 26984315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attenuation of ocular hypertension with the use of topical loteprednol etabonate 0.5% in steroid responders after corneal transplantation.
    Holland EJ; Djalilian AR; Sanderson JP
    Cornea; 2009 Dec; 28(10):1139-43. PubMed ID: 19770719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Change in intraocular pressure during long-term use of loteprednol etabonate.
    Novack GD; Howes J; Crockett RS; Sherwood MB
    J Glaucoma; 1998 Aug; 7(4):266-9. PubMed ID: 9713785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intraocular pressure response to loteprednol etabonate in known steroid responders.
    Bartlett JD; Horwitz B; Laibovitz R; Howes JF
    J Ocul Pharmacol; 1993; 9(2):157-65. PubMed ID: 8345288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological validation of a feline model of steroid-induced ocular hypertension.
    Bhattacherjee P; Paterson CA; Spellman JM; Graff G; Yanni JM
    Arch Ophthalmol; 1999 Mar; 117(3):361-4. PubMed ID: 10088814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loteprednol etabonate ophthalmic gel 0.5%: a review of its use in post-operative inflammation and pain following ocular surgery.
    Lyseng-Williamson KA
    Drugs; 2013 Jun; 73(9):949-58. PubMed ID: 23740411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5% for postoperative inflammation. Loteprednol Etabonate Post-operative Inflammation Study Group 1.
    Stewart R; Horwitz B; Howes J; Novack GD; Hart K
    J Cataract Refract Surg; 1998 Nov; 24(11):1480-9. PubMed ID: 9818338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Loteprednol Etabonate US Uveitis Study Group.
    Am J Ophthalmol; 1999 May; 127(5):537-44. PubMed ID: 10334346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of ketorolac tromethamine 0.5% and loteprednol etabonate 0.5% for inflammation after phacoemulsification: prospective randomized double-masked study.
    Holzer MP; Solomon KD; Sandoval HP; Vroman DT
    J Cataract Refract Surg; 2002 Jan; 28(1):93-9. PubMed ID: 11777716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis. Loteprednol Allergic Conjunctivitis Study Group.
    Dell SJ; Shulman DG; Lowry GM; Howes J
    Am J Ophthalmol; 1997 Jun; 123(6):791-7. PubMed ID: 9535623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the safety and efficacy of loteprednol 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of blepharokeratoconjunctivitis.
    White EM; Macy JI; Bateman KM; Comstock TL
    Curr Med Res Opin; 2008 Jan; 24(1):287-96. PubMed ID: 18062846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized controlled trial comparing dexamethasone with loteprednol etabonate on postoperative photorefractive keratectomy.
    Thanathanee O; Sriphon P; Anutarapongpan O; Athikulwongse R; Thongphiew P; Rangsin R; Suwan-apichon O
    J Ocul Pharmacol Ther; 2015 Apr; 31(3):165-8. PubMed ID: 25555173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis.
    Asbell P; Howes J
    CLAO J; 1997 Jan; 23(1):31-6. PubMed ID: 9001768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of loteprednol etabonate for treatment of papillae in contact lens-associated giant papillary conjunctivitis.
    Bartlett JD; Howes JF; Ghormley NR; Amos JF; Laibovitz R; Horwitz B
    Curr Eye Res; 1993 Apr; 12(4):313-21. PubMed ID: 8319490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.